Cargando…

Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study

BACKGROUND: Transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) are effective treatment methods for unresectable hepatocellular carcinoma (HCC). However, there is still a lack of clinical research on whether early sequential RFA, compared with late combination therapy, can impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Liangliang, Ren, Yanqiao, Qian, Kun, Kan, Xuefeng, Zhang, Hongsen, Chen, Lei, Liang, Bin, Zheng, Chuansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056675/
https://www.ncbi.nlm.nih.gov/pubmed/33879085
http://dx.doi.org/10.1186/s12876-021-01765-x
_version_ 1783680695425564672
author Yan, Liangliang
Ren, Yanqiao
Qian, Kun
Kan, Xuefeng
Zhang, Hongsen
Chen, Lei
Liang, Bin
Zheng, Chuansheng
author_facet Yan, Liangliang
Ren, Yanqiao
Qian, Kun
Kan, Xuefeng
Zhang, Hongsen
Chen, Lei
Liang, Bin
Zheng, Chuansheng
author_sort Yan, Liangliang
collection PubMed
description BACKGROUND: Transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) are effective treatment methods for unresectable hepatocellular carcinoma (HCC). However, there is still a lack of clinical research on whether early sequential RFA, compared with late combination therapy, can improve the long-term efficacy of initial TACE treatment. METHODS: This retrospective study investigated a cohort of patients who underwent combination therapy using TACE and RFA (TACE followed by RFA) from January 2010 to January 2020 at our medical centre. A total of 96 patients underwent TACE combined with early RFA (usually during the first hospitalization), which was called TACE + eRFA. Thirty-four patients received 1–2 palliative TACE treatments first and then underwent TACE treatment combined with late RFA (TACE + lRFA). All patients continued to receive palliative TACE treatments after intrahepatic lesion progression until reaching intolerance. The overall survival (OS) rate, time to tumour progression (TTP), tumour response rate and major complication rates were compared between the two groups. RESULTS: There were significant differences in the median OS (46 months vs 33 months; P = 0.013), median TTP (28 months vs 14 months; P < 0.00), objective response rate (ORR) (89.6% vs 61.8%, P = 0.000) and disease control rate (DCR) (94.8% vs 73.5% P = 0.002) between the two groups. Multivariable analysis revealed that the Barcelona Clinic Liver Cancer stage was an independent risk factor for OS. Meanwhile, multivariable analysis revealed that TACE + eRFA was associated with an enhanced TTP. CONCLUSION: Early sequential RFA treatment in patients with early-intermediate HCC can improve local tumour control and clinical outcomes while reducing the frequency of TACE treatment. In clinical practice, in HCC patients initially treated with TACE, it is recommended to combine RFA as soon as possible to obtain long-term survival.
format Online
Article
Text
id pubmed-8056675
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80566752021-04-21 Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study Yan, Liangliang Ren, Yanqiao Qian, Kun Kan, Xuefeng Zhang, Hongsen Chen, Lei Liang, Bin Zheng, Chuansheng BMC Gastroenterol Research BACKGROUND: Transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) are effective treatment methods for unresectable hepatocellular carcinoma (HCC). However, there is still a lack of clinical research on whether early sequential RFA, compared with late combination therapy, can improve the long-term efficacy of initial TACE treatment. METHODS: This retrospective study investigated a cohort of patients who underwent combination therapy using TACE and RFA (TACE followed by RFA) from January 2010 to January 2020 at our medical centre. A total of 96 patients underwent TACE combined with early RFA (usually during the first hospitalization), which was called TACE + eRFA. Thirty-four patients received 1–2 palliative TACE treatments first and then underwent TACE treatment combined with late RFA (TACE + lRFA). All patients continued to receive palliative TACE treatments after intrahepatic lesion progression until reaching intolerance. The overall survival (OS) rate, time to tumour progression (TTP), tumour response rate and major complication rates were compared between the two groups. RESULTS: There were significant differences in the median OS (46 months vs 33 months; P = 0.013), median TTP (28 months vs 14 months; P < 0.00), objective response rate (ORR) (89.6% vs 61.8%, P = 0.000) and disease control rate (DCR) (94.8% vs 73.5% P = 0.002) between the two groups. Multivariable analysis revealed that the Barcelona Clinic Liver Cancer stage was an independent risk factor for OS. Meanwhile, multivariable analysis revealed that TACE + eRFA was associated with an enhanced TTP. CONCLUSION: Early sequential RFA treatment in patients with early-intermediate HCC can improve local tumour control and clinical outcomes while reducing the frequency of TACE treatment. In clinical practice, in HCC patients initially treated with TACE, it is recommended to combine RFA as soon as possible to obtain long-term survival. BioMed Central 2021-04-20 /pmc/articles/PMC8056675/ /pubmed/33879085 http://dx.doi.org/10.1186/s12876-021-01765-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yan, Liangliang
Ren, Yanqiao
Qian, Kun
Kan, Xuefeng
Zhang, Hongsen
Chen, Lei
Liang, Bin
Zheng, Chuansheng
Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study
title Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study
title_full Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study
title_fullStr Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study
title_full_unstemmed Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study
title_short Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study
title_sort sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056675/
https://www.ncbi.nlm.nih.gov/pubmed/33879085
http://dx.doi.org/10.1186/s12876-021-01765-x
work_keys_str_mv AT yanliangliang sequentialtransarterialchemoembolizationandearlyradiofrequencyablationimprovesclinicaloutcomesforearlyintermediatehepatocellularcarcinomaina10yearsinglecentercomparativestudy
AT renyanqiao sequentialtransarterialchemoembolizationandearlyradiofrequencyablationimprovesclinicaloutcomesforearlyintermediatehepatocellularcarcinomaina10yearsinglecentercomparativestudy
AT qiankun sequentialtransarterialchemoembolizationandearlyradiofrequencyablationimprovesclinicaloutcomesforearlyintermediatehepatocellularcarcinomaina10yearsinglecentercomparativestudy
AT kanxuefeng sequentialtransarterialchemoembolizationandearlyradiofrequencyablationimprovesclinicaloutcomesforearlyintermediatehepatocellularcarcinomaina10yearsinglecentercomparativestudy
AT zhanghongsen sequentialtransarterialchemoembolizationandearlyradiofrequencyablationimprovesclinicaloutcomesforearlyintermediatehepatocellularcarcinomaina10yearsinglecentercomparativestudy
AT chenlei sequentialtransarterialchemoembolizationandearlyradiofrequencyablationimprovesclinicaloutcomesforearlyintermediatehepatocellularcarcinomaina10yearsinglecentercomparativestudy
AT liangbin sequentialtransarterialchemoembolizationandearlyradiofrequencyablationimprovesclinicaloutcomesforearlyintermediatehepatocellularcarcinomaina10yearsinglecentercomparativestudy
AT zhengchuansheng sequentialtransarterialchemoembolizationandearlyradiofrequencyablationimprovesclinicaloutcomesforearlyintermediatehepatocellularcarcinomaina10yearsinglecentercomparativestudy